Predicting response to switching from phosphodiesterase type 5 inhibitor to riociguat in patients with pulmonary arterial hypertension: biomarker and responder analysis of the RESPITE and REPLACE studies
This exploratory analysis assessed whether plasma biomarkers predict the response to switching from phosphodiesterase type 5 inhibitors (PDE5is) to the soluble guanylate cyclase stimulator riociguat in patients with pulmonary arterial hypertension. Selected biomarkers at baseline and their changes t...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 2025
|
| In: |
Pulmonary circulation
Year: 2025, Jahrgang: 15, Heft: 3, Pages: 1-12 |
| ISSN: | 2045-8940 |
| DOI: | 10.1002/pul2.70140 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/pul2.70140 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/pul2.70140 
|
| Verfasserangaben: | James R. Klinger, Hikmet Al-Hiti, Sung-A. Chang, Hyuk J. Chang, Hossein-Ardeschir Ghofrani, Ekkehard Grünig, Marius M. Hoeper, Pavel Jansa, Jaquelina Ota-Arakaki, Tomas Pulido, Gérald Simonneau, Carmine Dario Vizza, Claudia Rahner, Christian Meier, Gisela Meyer |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1951143957 | ||
| 003 | DE-627 | ||
| 005 | 20260204141247.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260204s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/pul2.70140 |2 doi | |
| 035 | |a (DE-627)1951143957 | ||
| 035 | |a (DE-599)KXP1951143957 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Klinger, James R. |e VerfasserIn |0 (DE-588)1388953900 |0 (DE-627)1951144333 |4 aut | |
| 245 | 1 | 0 | |a Predicting response to switching from phosphodiesterase type 5 inhibitor to riociguat in patients with pulmonary arterial hypertension |b biomarker and responder analysis of the RESPITE and REPLACE studies |c James R. Klinger, Hikmet Al-Hiti, Sung-A. Chang, Hyuk J. Chang, Hossein-Ardeschir Ghofrani, Ekkehard Grünig, Marius M. Hoeper, Pavel Jansa, Jaquelina Ota-Arakaki, Tomas Pulido, Gérald Simonneau, Carmine Dario Vizza, Claudia Rahner, Christian Meier, Gisela Meyer |
| 264 | 1 | |c July 2025 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 14. August 2025 | ||
| 500 | |a Gesehen am 04.02.2026 | ||
| 520 | |a This exploratory analysis assessed whether plasma biomarkers predict the response to switching from phosphodiesterase type 5 inhibitors (PDE5is) to the soluble guanylate cyclase stimulator riociguat in patients with pulmonary arterial hypertension. Selected biomarkers at baseline and their changes to Week 24 were evaluated in patients with and without a favorable response to riociguat in two trials: RESPITE, in which patients with an inadequate response to PDE5i were switched to riociguat; and REPLACE, in which patients at intermediate risk of 1-year mortality despite a PDE5i were randomized to remain on PDE5i or were switched to riociguat. A response was defined as absence of clinical worsening and at least two of the following criteria: 6-min walk distance increase by 10% or ≥ 30 m, World Health Organization functional class I/II, or N-terminal prohormone of brain natriuretic peptide reduction of ≥ 30% at Week 24. In REPLACE, responders had significantly higher baseline cyclic guanosine monophosphate (cGMP) and significantly lower baseline asymmetric dimethylarginine, and growth/differentiation factor 15 (GDF-15) than nonresponders. In RESPITE, responders had lower baseline GDF-15 than nonresponders, and nonresponders showed a significantly greater decrease in cGMP than responders. No baseline threshold value of any biomarker provided a good likelihood of predicting the response to riociguat. Overall, the biomarkers evaluated did not help to identify patients who were more likely to respond to switching from PDE5is to riociguat. | ||
| 650 | 4 | |a risk assessment | |
| 650 | 4 | |a soluble guanylate cyclase stimulators | |
| 650 | 4 | |a treatment guidelines | |
| 700 | 1 | |a Al-Hiti, Hikmet |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chang, Sung-A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chang, Hyuk J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ghofrani, Hossein-Ardeschir |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grünig, Ekkehard |e VerfasserIn |0 (DE-588)112535801 |0 (DE-627)618892605 |0 (DE-576)31856694X |4 aut | |
| 700 | 1 | |a Hoeper, Marius M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jansa, Pavel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ota-Arakaki, Jaquelina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pulido, Tomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Simonneau, Gérald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vizza, Carmine Dario |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rahner, Claudia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meier, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meyer, Gisela |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pulmonary circulation |d Hoboken, NJ : Wiley, 2011 |g 15(2025), 3 vom: Juli, Artikel-ID e70140, Seite 1-12 |h Online-Ressource |w (DE-627)672806649 |w (DE-600)2638089-4 |w (DE-576)353570435 |x 2045-8940 |7 nnas |a Predicting response to switching from phosphodiesterase type 5 inhibitor to riociguat in patients with pulmonary arterial hypertension biomarker and responder analysis of the RESPITE and REPLACE studies |
| 773 | 1 | 8 | |g volume:15 |g year:2025 |g number:3 |g month:07 |g elocationid:e70140 |g pages:1-12 |g extent:12 |a Predicting response to switching from phosphodiesterase type 5 inhibitor to riociguat in patients with pulmonary arterial hypertension biomarker and responder analysis of the RESPITE and REPLACE studies |
| 856 | 4 | 0 | |u https://doi.org/10.1002/pul2.70140 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/pul2.70140 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260204 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 112535801 |a Grünig, Ekkehard |m 112535801:Grünig, Ekkehard |d 50000 |d 910000 |d 950000 |d 950900 |e 50000PG112535801 |e 910000PG112535801 |e 950000PG112535801 |e 950900PG112535801 |k 0/50000/ |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 6 | ||
| 999 | |a KXP-PPN1951143957 |e 4876490813 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1951143957","note":["Online verfügbar: 14. August 2025","Gesehen am 04.02.2026"],"name":{"displayForm":["James R. Klinger, Hikmet Al-Hiti, Sung-A. Chang, Hyuk J. Chang, Hossein-Ardeschir Ghofrani, Ekkehard Grünig, Marius M. Hoeper, Pavel Jansa, Jaquelina Ota-Arakaki, Tomas Pulido, Gérald Simonneau, Carmine Dario Vizza, Claudia Rahner, Christian Meier, Gisela Meyer"]},"id":{"eki":["1951143957"],"doi":["10.1002/pul2.70140"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"July 2025"}],"relHost":[{"part":{"extent":"12","year":"2025","issue":"3","volume":"15","text":"15(2025), 3 vom: Juli, Artikel-ID e70140, Seite 1-12","pages":"1-12"},"title":[{"title_sort":"Pulmonary circulation","subtitle":"official journal of the Pulmonary Vascular Research Institute","title":"Pulmonary circulation"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"2011-","publisherPlace":"Hoboken, NJ ; Mumbai ; Chicago, Ill. ; Thousand Oaks, CA","publisher":"Wiley ; Medknow Publ. ; Univ. of Chicago Press ; Sage Publications","dateIssuedKey":"2011"}],"id":{"issn":["2045-8940"],"zdb":["2638089-4"],"eki":["672806649"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"pubHistory":["1.2011 -"],"recId":"672806649","note":["Gesehen am 26.07.2024"],"disp":"Predicting response to switching from phosphodiesterase type 5 inhibitor to riociguat in patients with pulmonary arterial hypertension biomarker and responder analysis of the RESPITE and REPLACE studiesPulmonary circulation"}],"person":[{"given":"James R.","family":"Klinger","display":"Klinger, James R.","role":"aut"},{"display":"Al-Hiti, Hikmet","family":"Al-Hiti","given":"Hikmet","role":"aut"},{"role":"aut","family":"Chang","display":"Chang, Sung-A.","given":"Sung-A."},{"role":"aut","given":"Hyuk J.","display":"Chang, Hyuk J.","family":"Chang"},{"role":"aut","display":"Ghofrani, Hossein-Ardeschir","family":"Ghofrani","given":"Hossein-Ardeschir"},{"given":"Ekkehard","display":"Grünig, Ekkehard","family":"Grünig","role":"aut"},{"given":"Marius M.","family":"Hoeper","display":"Hoeper, Marius M.","role":"aut"},{"role":"aut","family":"Jansa","display":"Jansa, Pavel","given":"Pavel"},{"display":"Ota-Arakaki, Jaquelina","family":"Ota-Arakaki","given":"Jaquelina","role":"aut"},{"display":"Pulido, Tomas","family":"Pulido","given":"Tomas","role":"aut"},{"role":"aut","given":"Gérald","family":"Simonneau","display":"Simonneau, Gérald"},{"role":"aut","display":"Vizza, Carmine Dario","family":"Vizza","given":"Carmine Dario"},{"family":"Rahner","display":"Rahner, Claudia","given":"Claudia","role":"aut"},{"role":"aut","given":"Christian","family":"Meier","display":"Meier, Christian"},{"role":"aut","display":"Meyer, Gisela","family":"Meyer","given":"Gisela"}],"title":[{"title":"Predicting response to switching from phosphodiesterase type 5 inhibitor to riociguat in patients with pulmonary arterial hypertension","subtitle":"biomarker and responder analysis of the RESPITE and REPLACE studies","title_sort":"Predicting response to switching from phosphodiesterase type 5 inhibitor to riociguat in patients with pulmonary arterial hypertension"}],"physDesc":[{"extent":"12 S."}]} | ||
| SRT | |a KLINGERJAMPREDICTING2025 | ||